Bright Minds to Raise $35 M Via Non-Brokered Private Placement
DENVER, Colo., Oct 18, 2024 (247marketnews.com)- Bright Minds (NASDAQ: DRUG) stated that it agreed to a non-brokered private placement of the Company’s common shares at USD$21.70 per share. Additionally, Bright Minds reserves the right to issue pre-funded warrants of the Company (“PFWs”) at USD$21.699 per PFW.
The combined aggregate offering gross proceeds is for up to USD$35,000,000, less fess, which Bright Minds intends to use for research and development related to its drug development programs, and general working capital.
The Offering was executed in accordance with applicable Canadian securities laws, so the securities issued in connection with the offering are subject to a statutory hold period of four months and one day from the closing date.
MoBot alerted Bright Minds (NASDAQ: DRUG) on Monday at $1.426 and it nearly hit $60 in Tuesday’s afterhours on over 100 million shares traded that day.
Please go to 247marketnews.com to sign up for free MoBot alerts and view Mobot’s real time data
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (DRUG)
- Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025
- Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101
- Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study
- Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research
- Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer